The medication management platform sees strong growth in the US after its “transformational” acquisition 6 months ago.
The post Why the MedAdvisor (ASX:MDR) share price jumped 12% today appeared first on The Motley Fool Australia. –
The medication management platform provider’s shares are currently up 12% to 32.5 cents.
Why did the MedAdvisor share price push higher?
MedAdvisor has provided a business update 6 months after its acquisition of US-based patient management solutions platform, Adheris.
In today’s statement, MedAdvisor advised that its revenue had growth 40% on a like-for-like basis for the 9 months year-to-date for FY21.
MedAdvisor is leveraging Adheris’ extensive network of approximately 25,000 pharmacies and 2.2 billion scripts annual to bring additional scale to its digital capabilities.
The rollout of MedAdvisor’s digital solutions through the Adheris network is well underway. In June, 17% of the Adheris pharmacy network was scheduled to be digital, and a further 13% is expected in the September quarter.
Pleasingly, this will bring the company’s profile of digitally contactable patients in the US to approximately 42 million, or 20 times its present digital reach in Australia.
Additionally, MedAdvisor has rolled out 7 digital programs for pharmaceutical companies in the US. The company says that on average, patients who join the digital program demonstrate an improved adherence of up to 30%, leading to 1–2 extra script fills per year. The company says this results in improved health outcomes for the patients and more consistent revenue for the pharmacy.
MedAdvisor US President, John Ciccio comments on the company’s achievements in the US:
We’ve invested in providing the sales and marketing team with the resources required to go deeper with existing clients and expand our customer base. We’ve added new customers and brands to our network in the past 6 months and we’re selling more multi-tactic programs that include digital.
By expanding its digital offering, MedAdvisor is able to significantly boost the attractiveness of its product suite to its client base. As an example, one top ten pharmaceutical client who has averaged USD$125k p.a. with Adheris over the last 2 years has now signed a multi-channel deal for USD$1 million for CY21.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of May 24th 2021
Charter Hall REIT (ASX:CLW) share price flat on notes issuance
Here’s why the Centuria (ASX:CNI) share price is gaining
Why has IDP Education (ASX:IEL) share price risen 33% in the last 12 months?
2 quality healthcare options for ASX investors
Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended MedAdvisor. The Motley Fool Australia has recommended MedAdvisor. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.